Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia. - Wikidata - awgldk - TriplyDB

Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia.

Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia.

http://www.wikidata.org/entity/Q43133053

about

Lipid-lowering efficacy of rosuvastatin Familial hypercholesterolemia: Review of diagnosis, screening, and treatment Familial hypercholesterolemia: present and future management Pediatric Statin Administration: Navigating a Frontier with Limited Data PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future Long-term pharmacotherapy for elevated low density lipoprotein levels in children: A retrospective analysis The safety of statins in children.Optimal management of familial hypercholesterolemia: treatment and management strategies Rosuvastatin: a review of the pharmacology and clinical effectiveness in cardiovascular disease.PCSK9 inhibition to reduce cardiovascular disease risk: recent findings from the biology of PCSK9.Additive beneficial effects of valsartan combined with rosuvastatin in the treatment of hypercholesterolemic hypertensive patients Safety of statins.Lowering serum lipids via PCSK9-targeting drugs: current advances and future perspectives.What matters most in pediatric familial hypercholesterolemia, genotype or phenotype?Long-term follow-up of statin treatment in a cohort of children with familial hypercholesterolemia: efficacy and tolerability.Drug safety evaluation of rosuvastatin.Is the future of statins aligned with new novel lipid modulation therapies?Early diagnosis and treatment of familial hypercholesterolemia: improving patient outcomes.Lipid lowering with PCSK9 inhibitors.Emerging innovative therapeutic approaches targeting PCSK9 to lower lipids.Statin therapy across the lifespan: evidence in major age groups.Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis.Alirocumab for the treatment of hypercholesterolaemia.Bayesian average error-based approach to sample size calculations for hypothesis testing.Population pharmacokinetics of rosuvastatin in pediatric patients with heterozygous familial hypercholesterolemia.Atorvastatin safety in Kawasaki disease patients with coronary artery aneurysms.Hypercholestérolémie familiale: Révision du diagnostic, du dépistage et du traitement.Impact of Lipid Measurements in Youth in Addition to Conventional Clinic-Based Risk Factors on Predicting Preclinical Atherosclerosis in Adulthood: The International Childhood Cardiovascular Cohort (i3C) Consortium.Recommendations to Enhance Pediatric Cardiovascular Drug Development: Report of a Multi-Stakeholder Think Tank.Treatment of familial hypercholesterolaemia in children and adolescents in the last three decades.Secondary Dyslipidemia In Obese Children - Is There Evidence For Pharmacological Treatment?

P2860

Q24187891-F6E59465-904B-4758-82CD-063432624BE6 Q26770143-8245E8B1-41CE-40B1-B214-61020E55DD1D Q26828489-56311647-08B4-4A1E-9C8D-3804F7EF83DD Q28068014-5B6F0A69-AE99-4436-8B70-7CA54FD393EF Q28083595-E747326A-F929-40B9-9ED1-06745D7D666E Q33924782-B993072E-85E3-487D-B400-921D2879D1CD Q34342024-3C6D1255-A8A2-4395-B947-96389641A832 Q34417480-C4DEE33F-1853-4BD3-B7FB-C5F629273680 Q34636887-930DBD39-458C-4A51-9137-141A99C1AA31 Q35262593-35276C7C-F876-4094-96A7-49B6CF2E9980 Q35658419-3CDEDAC8-3E83-4907-8DFF-11179600DCC1 Q37095088-2A12E4A5-2B79-474F-AB00-917EA8CE9D90 Q37688760-796F5697-74B7-47D9-9C72-A8965674EBFB Q37716338-17095C85-C88E-4144-8306-C76A7D648B17 Q37892524-8253946F-0CEC-48E2-A032-36D88ADA2CAB Q37945657-312EE14B-AE2B-43EA-821E-DBF0F9C204AF Q38073148-01874A72-A2C5-458D-A5AC-C86D6CE07BA9 Q38087382-292D080F-97FE-42F3-8009-CB47142A6667 Q38222649-E9BCE42C-D5C0-45C6-B7AC-D0F7B8891509 Q38613935-D96E0B08-6C9E-42C6-B15B-2991F8AD9DBD Q38660929-DB0B7D8A-3492-4E64-BFAE-663F493E6EC6 Q38786058-EDA57A15-7ED5-4C30-BD67-306CD7444E4B Q38843982-CE688F44-B1D2-4191-8A65-4523F28B811D Q40301996-AC29B63E-EA2D-4A94-BAD8-131A5D1D6AC9 Q40521213-A92E195C-13FE-4ADE-B421-08059DD3393F Q46814711-B1D32F33-DD7B-4EAF-AF27-E485A03E7DC7 Q46840217-D2FE055C-711D-4AF0-B6E9-FA8345493D5F Q47319515-84FC9658-96A9-4616-B94A-1E135B4BD33C Q50027860-6C859174-9AB8-41A0-8105-88D22858253F Q51007698-32923B39-1556-4F55-A06D-F1D1BB60510F Q58772783-C449F0DA-993F-4C8F-A5E6-148942F9BDAF

P2860

Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia.

http://www.wikidata.org/entity/Q43133053

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh-hant

name

Efficacy and safety of rosuvas ...... familial hypercholesterolemia.

@en

Efficacy and safety of rosuvas ...... familial hypercholesterolemia.

@nl

type

label

Efficacy and safety of rosuvas ...... familial hypercholesterolemia.

@en

Efficacy and safety of rosuvas ...... familial hypercholesterolemia.

@nl

prefLabel

Efficacy and safety of rosuvas ...... familial hypercholesterolemia.

@en

Efficacy and safety of rosuvas ...... familial hypercholesterolemia.

@nl

P1433

Q43133053-C00A763A-761A-4D95-8599-569F414B274A

P1476

Q43133053-D4E36B9E-1CAA-40E6-9329-9D092C6A39E7

P2093

Q43133053-073101B9-E3E3-466E-ADFC-2B2D1B1E8FC9

Q43133053-15E47299-1ABD-4A3A-A39F-103B531E66F0

Q43133053-3F35367A-BD36-43C5-A9AA-01D5D9BADDB3

Q43133053-45F6E1D5-D627-4539-B4BA-B828390EA7C3

Q43133053-543CC7E4-306E-4AAA-9790-EA8FD5DEFA08

Q43133053-6692EE08-A42E-4F01-A594-269F744537BD

Q43133053-7B2BE63C-7E73-471F-A103-0DB6F345A832

Q43133053-867B1FBE-FD3D-4C4F-A986-74A2CEDF3BD9

Q43133053-EB43EAF2-4009-4B39-A03A-1658155D5011

P304

Q43133053-19E981A3-26D7-482A-88EE-7B47EA64748E

P31

Q43133053-03C0CB26-3136-426A-9CFA-229244DE064E

P356

Q43133053-BF317A9D-0B37-45C0-BC61-4CECADE69DE0

P407

Q43133053-02E8D4DF-8EA6-4695-9166-D1E522E4F916

P433

Q43133053-8D3E4136-D293-479A-8370-B34CBF2B36FB

P478

Q43133053-AC8EFB8A-09A8-402B-9941-DC15D3466A37

P577

Q43133053-6CC5849C-10B5-428D-9EDC-2C931049A54C

P5875

Q43133053-E24F0743-45C5-44A1-8950-4CFA5EA32B48

P698

Q43133053-191AA9FA-1CB9-4ABD-A64C-5145238FB526

P921

Q43133053-B3C33FE9-ABC0-4D15-A9C8-EEB6200A5CD0

P356

J.JACC.2009.10.042

P1433

Journal of the American College of Cardiology

P1476

Efficacy and safety of rosuvas ...... familial hypercholesterolemia.

@en

P2093

Albert Wiegman

http://www.w3.org/2001/XMLSchema#string

Barbara A Hutten

http://www.w3.org/2001/XMLSchema#string

Brian W McCrindle

http://www.w3.org/2001/XMLSchema#string

Claude Gagné

http://www.w3.org/2001/XMLSchema#string

Evan A Stein

http://www.w3.org/2001/XMLSchema#string

Gisle Langslet

http://www.w3.org/2001/XMLSchema#string

Hans J Avis

http://www.w3.org/2001/XMLSchema#string

John J P Kastelein

http://www.w3.org/2001/XMLSchema#string

Judith Hsia

http://www.w3.org/2001/XMLSchema#string

P304

1121-1126

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JACC.2009.10.042

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

55

http://www.w3.org/2001/XMLSchema#string

P577

2010-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41909705

http://www.w3.org/2001/XMLSchema#string

P698

20223367

http://www.w3.org/2001/XMLSchema#string

P921

hypercholesterolemia